Alpelisib: Difference between revisions
m Open access bot: doi added to citation with #oabot. |
m Importing Wikidata short description: "Chemical compound" (Shortdesc helper) |
||
| Line 1: | Line 1: | ||
{{short description|Chemical compound}} |
|||
{{Use dmy dates|date=November 2019}} |
{{Use dmy dates|date=November 2019}} |
||
{{Infobox drug |
{{Infobox drug |
||
Revision as of 04:27, 23 July 2020
 | |
| Clinical data | |
|---|---|
| Trade names | Piqray |
| Other names | BYL719 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a619036 |
| License data | |
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| PubChem SID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.233.704 |
| Chemical and physical data | |
| Formula | C19H22F3N5O2S |
| Molar mass | 441.47 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Alpelisib (INN; development code BYL719; brand name Piqray) is a medication sold by Novartis and used to treat certain types of breast cancer.[1] It is used together with fulvestrant.[1] It is taken by mouth.[1]
Common side effects include high blood sugar, kidney problems, diarrhea, rash, low blood cells, liver problems, pancreatitis, vomiting, and hair loss.[1] It is an alpha-specific PI3K inhibitor.[1][2] It was approved for medical use in the United States in May 2019.[1]
History
In May 2019, alpelisib was approved in the United States for use in combination with the endocrine therapy fulvestrant, to treat postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen.[1]
The U.S. Food and Drug Administration (FDA) also approved the companion diagnostic test, therascreen PIK3CA RGQ PCR Kit, to detect the PIK3CA mutation in a tissue and/or a liquid biopsy.[1]
The efficacy of alpelisib was studied in the SOLAR-1 trial (NCT02437318), a randomized trial of 572 postmenopausal women and men with HR-positive, HER2-negative, advanced or metastatic breast cancer whose cancer had progressed while on or after receiving an aromatase inhibitor.[1][3]
The FDA granted the application for alpelisib priority review designation and granted approval of Piqray to Novartis. The FDA granted approval of the therascreen PIK3CA RGQ PCR Kit to Qiagen Manchester, Ltd.[1]
References
- ^ a b c d e f g h i j "FDA approves first PI3K inhibitor for breast cancer". U.S. Food and Drug Administration (FDA) (Press release). 24 May 2019. Archived from the original on 25 November 2019. Retrieved 29 May 2019.
This article incorporates text from this source, which is in the public domain.
- ^ André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. (May 2019). "PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer". The New England Journal of Medicine. 380 (20): 1929–1940. doi:10.1056/NEJMoa1813904. PMID 31091374.
- ^ "Drug Trials Snapshots: Piqray". U.S. Food and Drug Administration (FDA). 14 June 2019. Archived from the original on 25 November 2019. Retrieved 24 November 2019.
External links
- "Alpelisib". Drug Information Portal. U.S. National Library of Medicine.
- "Drug Approval Package: Piqray". U.S. Food and Drug Administration (FDA).
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |